首页> 外文期刊>Journal of viral hepatitis. >Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies
【24h】

Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies

机译:编码乙型肝炎病毒小表面和前S1抗原的重组Semliki Forest病毒载体诱导广泛反应的中和抗体

获取原文
获取原文并翻译 | 示例
           

摘要

Most hepatitis B virus (HBV) vaccines consist of viral small surface (S) protein subtype adw2 expressed in yeast cells. In spite of good efficacy, HBV-genotype and subtype differences, escape mutants and insufficient Th1 activation remain potential problems. To address these problems, we generated recombinant Semliki Forest virus (rSFV) vectors encoding S protein, subtype adw2 or ayw2, or a fragment of the large surface protein, amino acids 1-48 of the pre-S1 domain, fused to S (pre-S1.1-48/S). The antigen loop in S protein and the selected pre-S1 sequences are known targets of neutralizing antibodies. BALB/c mice were immunized intravenously with 10 7 rSFV particles and 10 8 rSFV particles 3 weeks later. Antibodies induced by rSFV encoding S proteins reacted preferentially with subtype determinants of yeast-derived S antigen but equally well with patient-derived S antigen. Immunization with rSFV encoding pre-S1.1-48/S resulted in formation of pre-S1- and S-specific immunoglobulin G (IgG), while immunization with the isogenic mutant without S start codon induced pre-S1 antibodies only. Neutralizing antibodies were determined by mixing with plasma-derived HBV/ayw2 and subsequent inoculation of susceptible primary hepatocyte cultures from Tupaia belangeri. S/adw2 antisera neutralized HBV/ayw2 as effectively as antisera raised with S/ayw2. The pre-S1 antibodies also completely neutralized HBV infectivity. The IgG1/IgG2a ratios ranged from 0.28 to 0.88 in the four immunized groups and were lowest for the pre-S1.1-48/S vector, indicating the strongest Th1 response. This vector type may induce subtype-independent and S-escape-resistant neutralizing antibodies against HBV.
机译:大多数乙型肝炎病毒(HBV)疫苗由在酵母细胞中表达的病毒小表面(S)蛋白亚型adw2组成。尽管疗效良好,但HBV基因型和亚型的差异,逃逸突变体和Th1激活不足仍然是潜在的问题。为了解决这些问题,我们生成了编码S蛋白,亚型adw2或ayw2或大表面蛋白片段(前S1域的氨基酸1-48)的重组Semliki Forest病毒(rSFV)载体,该片段与S(pre -S1.1-48 / S)。 S蛋白中的抗原环和选定的S1前序列是中和抗体的已知靶标。 3周后,用10 7个rSFV颗粒和10 8个rSFV颗粒静脉内免疫BALB / c小鼠。由rSFV编码的S蛋白诱导的抗体优先与酵母来源的S抗原的亚型决定簇反应,但与患者来源的S抗原同样反应良好。用编码pre-S1.1-48 / S的rSFV免疫导致形成pre-S1-和S特异性免疫球蛋白G(IgG),而用无S的同基因突变体的免疫仅起始密码子诱导的pre-S1抗体。通过与血浆来源的HBV / ayw2混合并随后接种来自Tupaia belangeri的易感原代肝细胞培养物来确定中和抗体。 S / adw2抗血清中和HBV / ayw2的效果与S / ayw2引起的抗血清一样有效。前S1抗体也完全中和了HBV感染性。在四个免疫组中,IgG1 / IgG2a的比率范围为0.28至0.88,对于S1.1-48 / S之前的载体最低,表明Th1反应最强。该载体类型可能诱导抗HBV的亚型独立和抗S逃逸的中和抗体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号